Immunome Overview
Valuation check: IMNM's ROE is -48.43%, below the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow-48.43%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Immunome (IMNM) currently reports a ROE of -48.43%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Immunome's ROE history and peer comparisons.
Immunome's ROE of -48.43% is lower than the Healthcare sector average of 20.86%. That is roughly 332.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Immunome's current -48.43% should be judged against Healthcare norms (sector average: 20.86%) and against IMNM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -48.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Immunome, and consider following IMNM for alerts when major investors trade the stock.
Immunome is classified in the Healthcare sector. On ROE, it currently shows -48.43% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMNM with unrelated industries.
